Nuformix Plc
NFX.XLON
Nuformix Plc is a pharmaceutical company that focuses on the development of cocrystal technology for novel outcomes in drug efficacy and delivery. The company's primary function is to utilize its expertise in pharmaceutical cocrystal intellectual property to improve drug formulation, enhancing bioavailability and therapeutic outcomes. Nuformix targets a wide array of medical and health sectors, with particular emphasis on treating cancer and fibrotic diseases. By developing compositions that enhance existing drug compounds, the company contributes significantly to the pharmaceutical supply chain, creating solutions that can lead to more effective drug therapies. Its strategic role within the financial market highlights the importance of innovation in the biotech sector, aimed at addressing unmet clinical needs and improving patient care. As Nuformix continues to leverage its proprietary technology, it remains a pivotal player in advancing drug development processes and therapeutic innovations.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
£0.00
Net Income (TTM)
-£653K
▲ +82.1% YoY
Op. Margin
–
ROIC
-70.98%
▼ -15.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-£615K
▼ -85.2% YoY
Op. Cash Flow (TTM)
-£615K
▼ -85.2% YoY
Net Debt
-£98K
Net Cash Position
Cash & Equiv.
£98K
Continue Research
Peers
Biotechnology · Pick stocks to compare with NFX.XLON
Nuformix (NFX.XLON) in three numbers
Questions about Nuformix
Is Nuformix a high-quality business?
Nuformix scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from company filings. Its best check is net debt at -$97550, and its weakest is return on capital at -71.0%. The Quality tab shows every check against its target.
Does Nuformix (NFX.XLON) pay a dividend?
No. Nuformix (NFX.XLON) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 13 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing NFX.XLON
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.